A Phase 2, Multi-Center, Double-Blinded, Placebo-Controlled Safety And Efficacy Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2010
At a glance
- Drugs Latrepirdine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 28 Jun 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 16 Feb 2010 New trial record